Alx Oncology Holdings Inc SEC Filings

Shelly Pinto, SVP Finance and CAO of ALX Oncology Holdings, Inc. (ALXO), reported a transaction on 08/15/2025. The filing shows the sale of 611 shares of the issuer's common stock at a weighted average price of $0.6404 per share, with sale prices ranging between $0.64 and $0.66. The registrant states the shares were sold to satisfy tax obligations related to the vesting of restricted stock units. Following the transaction, the reporting person beneficially owned 89,198 shares, which includes 3,000 shares acquired under the company's employee stock purchase plan on June 30, 2025. The Form 4 was signed on 08/19/2025.

ALX Oncology Holdings, Inc. (ALXO) director and Chief Executive Officer Jason Lettmann reported a small sale of Common Stock on 08/15/2025 to satisfy tax obligations from RSU vesting. The filing shows 2,382 shares sold at a weighted-average price of $0.6404 (sales occurred between $0.64 and $0.66). After the reported disposition, the reporting person beneficially owns 212,888 shares, which includes 3,000 shares acquired under the companys employee stock purchase plan on 06/30/2025. The Form 4 was signed by power of attorney on 08/19/2025.

Redmile Group, LLC and related parties report an 8.5% economic interest in ALX Oncology (ALXO). The filing discloses beneficial ownership of 4,641,455 shares in total, composed of 3,391,455 shares of common stock and 1,250,000 shares issuable upon exercise of warrants. Redmile Biopharma Investments III, L.P. holds 3,675,481 shares (6.7%). Percentages are calculated using 53,444,020 shares outstanding as of May 1, 2025 plus the 1,250,000 warrant shares. The reporters state shared voting and dispositive power and disclaim sole ownership beyond pecuniary interest.

Curran Daniel J., a director of ALX Oncology Holdings Inc. (ALXO), acquired a stock option grant for 40,400 shares on 08/12/2025. The option carries an exercise price of $0.615 and an expiration date of 08/11/2035. According to the filing, the shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025.

The Form 4 was filed by one reporting person and signed under power of attorney on 08/13/2025. The transaction is recorded as an acquisition of a derivative security whose underlying title is common stock; the ownership is reported as direct.

ALX Oncology Holdings reported unaudited Q2 2025 results showing total assets of $95.3 million and total stockholders' equity of $64.4 million. Cash and cash equivalents were $19.3 million with short-term investments of $60.0 million and long-term investments of $4.2 million, for a total fair-value investment balance of $81.8 million. The company recorded a net loss of $25.9 million for the three months ended June 30, 2025 and $56.7 million for the six months, and had an accumulated deficit of $677.8 million.

Operationally, R&D expense was $18.0 million in the quarter (down 48% year-over-year), driven by lower clinical and preclinical spend and reduced stock-based compensation. The company recognized a $3.2 million impairment charge related to a to-be-sublet Palo Alto property. Clinical highlights include ASPEN-06 Phase 2 signals: ITT ORR of 41.3% versus 26.6% TRP control and stronger benefit in CD47-high patients (e.g., ORR 65% in confirmed HER2+/CD47-high subgroup). The IND for ALX2004 was cleared in April 2025. The company received a Nasdaq minimum bid price notice on April 23, 2025 with a compliance period through October 20, 2025, and states existing capital resources are sufficient for at least the next 12 months.

ALX Oncology disclosed that it furnished a press release reporting financial results for the second quarter and full year ended June 30, 2025. The filing itself does not include the financial detail but references Exhibit 99.1 for the full release.

The company also expanded its board from six to seven members by appointing Daniel Curran, M.D. as a Class III director. Dr. Curran brings over 25 years of pharmaceutical experience, including recent roles as CEO of Timberlyne Therapeutics and prior senior leadership at Takeda. He will join the Corporate Governance and Nominating Committee and is designated as independent under applicable Nasdaq and SEC standards.

Under the outside director compensation policy Dr. Curran will receive an initial option award to purchase 40,400 shares that vests monthly over 36 months and will be eligible for annual cash and equity awards; an indemnification agreement was also executed. The filing lists updated board committee memberships.